Tarsus Pharmaceuticals Reports 147% Revenue Growth to $118.7 Million in Q3 2025

Tarsus Pharmaceuticals, Inc. reported significant financial growth in its latest quarterly filing, with total revenues reaching $118.7 million for the three months ended September 30, 2025, compared to $48.1 million for the same period in 2024. This represents a 147% increase year-over-year, primarily driven by the strong sales of its product XDEMVY, which accounted for $118.7 million in net product sales. For the nine months ended September 30, 2025, total revenues were $299.7 million, up from $116.5 million in the prior year. The company’s net loss for the third quarter was $12.6 million, a notable improvement from a loss of $23.4 million in the same quarter last year. For the nine-month period, the net loss was $58.0 million, down from $92.4 million in 2024.

The company’s operational metrics indicate a robust adoption of XDEMVY, with over 103,000 bottles delivered to patients in the third quarter of 2025, compared to approximately 41,400 bottles in the prior year. Tarsus has also expanded its customer base, with more than 20,000 eye care professionals (ECPs) prescribing the product, reflecting a growing confidence in its integration into clinical practice. The number of ECPs prescribing more than one bottle per week increased by approximately 30% compared to the previous quarter. The company has achieved broad coverage, with over 90% of commercial, Medicare, and Medicaid lives covered, leading to a gross-to-net discount of 44.7%.

In terms of expenses, Tarsus reported total operating expenses of $133.2 million for the third quarter of 2025, up from $73.3 million in the same quarter of 2024. This increase was driven by higher selling, general, and administrative expenses, which rose to $108.6 million from $57.9 million, largely due to increased marketing and personnel costs associated with the commercial launch of XDEMVY. Research and development expenses also increased to $16.3 million from $12.1 million, reflecting ongoing investments in product development.

Strategically, Tarsus has made significant advancements, including the successful launch of XDEMVY in August 2023 after receiving FDA approval. The company is also progressing with its pipeline, including investigational products TP-04 and TP-05, targeting ocular rosacea and Lyme disease prophylaxis, respectively. The company has plans for further clinical trials and expects to initiate a Phase 2 study for TP-04 in late 2025. As of September 30, 2025, Tarsus reported cash, cash equivalents, and marketable securities totaling $401.8 million, which the company believes is sufficient to fund its operations for at least the next twelve months.

Looking ahead, Tarsus anticipates continued growth in product sales and is focused on expanding its market presence. The company is also aware of the potential need for additional capital to support its ongoing operations and product development initiatives. Management has indicated that while they expect to incur operating losses in the near term, they are committed to advancing their product candidates and maintaining regulatory approvals for XDEMVY.